Comparative Pharmacology
Head-to-head clinical analysis: MIOCHOL versus MIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIOCHOL versus MIOSTAT.
MIOCHOL vs MIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miochol (acetylcholine chloride) is a direct-acting cholinergic agonist that binds to and activates muscarinic receptors, causing miosis (pupil constriction) and contraction of the ciliary muscle, thereby facilitating intraocular surgery.
MIOSTAT (carbachol intraocular solution) is a cholinergic agent that mimics the effects of acetylcholine, causing miosis (pupil constriction) by stimulating muscarinic receptors on the sphincter muscle of the iris.
Intraocular injection of 0.5 mL of a 1:100 (10 mg/mL) solution into the anterior chamber to achieve miosis within seconds.
Intracameral injection of 0.01 mg (0.5 mL of 0.02 mg/mL solution) as a single dose during surgery.
None Documented
None Documented
Plasma half-life is approximately 2-3 minutes due to rapid enzymatic hydrolysis; clinical effect is brief and intraocular effect lasts only during the surgical procedure.
Intraocular half-life approximately 1-2 hours; systemic half-life negligible due to rapid metabolism.
Miochol (acetylcholine chloride) is rapidly hydrolyzed by acetylcholinesterase in the blood and tissues; less than 1% is excreted unchanged in urine. No significant biliary or fecal elimination.
Primarily via intraocular metabolism; systemic absorption minimal. No significant renal or biliary excretion.
Category C
Category C
Ophthalmic Miotic
Ophthalmic Miotic